A Phase 1, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetics Study of PRA023 in Healthy Volunteers
Latest Information Update: 19 Jan 2024
At a glance
- Drugs Tulisokibart (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Systemic scleroderma; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Prometheus Biosciences
- 28 Mar 2022 Status changed from active, no longer recruiting to completed.
- 07 Dec 2021 According to a Prometheus Biosciences media release, the company will host a video webcast to discuss results from this trial.
- 07 Dec 2021 Results published in the Prometheus Biosciences Media Release.